Recombinant Hepatitis B Vaccine Approved for Clinical Trials to Prevent HBsAg Rebound in Clinically Cured Chronic Hepatitis B Patients
December 18, 2025
Source: drugdu
30
BioKangtai (300601): Recombinant Hepatitis B Vaccine Approved for Clinical Trials to Prevent HBsAg Rebound in Clinically Cured Chronic Hepatitis B Populations
PEOPLE’S FINANCE NEWS, December 17 — Shenzhen Kangtai Biological Products Co., Ltd. (BioKangtai, 300601.SZ) announced on December 17 that its self-developed Recombinant Hepatitis B Vaccine (Saccharomyces cerevisiae) (60μg) has received a "Drug Clinical Trial Approval Notice" from the National Medical Products Administration (NMPA) for a new indicated population.
The notice approves clinical trials of this vaccine to prevent HBsAg seroreversion (rebound) in populations who have achieved functional (clinical) cure for chronic hepatitis B.
https://finance.eastmoney.com/a/202512173594363010.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- A new ADC champion has emerged. December 18, 2025
- Domestic ophthalmic monoclonal antibody achieves blockbuster BD December 18, 2025
- Clinical trial application for nasal spray accepted, targeting allergic rhinitis. December 18, 2025
- New drug JSKN027 accepted for clinical trials December 18, 2025
- WHO Warns Europe’s Influenza Peak May Arrive by Year-End December 18, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
